Dual gene activation and knockout screen reveals directional dependencies in genetic networks

Nature Biotechnology

Volumn 36, Issue 2, 2018, Pages 170-178

  Boettcher, Michael ^a   Tian, Ruilin ^a   Blau, James A ^a   Markegard, Evan ^b   Wagner, Ryan T ^a   Wu, David ^a   Mo, Xiulei ^c   Biton, Anne ^a,d   Zaitlen, Noah ^a   Fu, Haian ^c   McCormick, Frank ^b   Kampmann, Martin ^a   McManus, Michael T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Centre de Bioinformatique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; CHEMICAL ACTIVATION;

DEPENDENCY NETWORKS; GENETIC INTERACTION; INFORMATION FLOWS; INTERACTION NETWORKS; QUANTITATIVE EFFECTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; THERAPEUTIC INTERVENTION;

GENE THERAPY;

BCR ABL PROTEIN; BREAST CANCER RESISTANCE PROTEIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CELL VIABILITY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DRUG TOLERANCE; GENE ACTIVATION; GENE INTERACTION; GENETIC SCREENING; HEK293T CELL LINE; HUMAN; HUMAN CELL; IC50; K-562 CELL LINE; LEUKEMIA; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; BIOLOGY; EPISTASIS; GENE KNOCKOUT; GENE REGULATORY NETWORK; GENETICS; TRANSCRIPTION INITIATION;

COMPUTATIONAL BIOLOGY; CRISPR-ASSOCIATED PROTEIN 9; EPISTASIS, GENETIC; GENE KNOCKOUT TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; K562 CELLS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TRANSCRIPTIONAL ACTIVATION;

EID: 85041478284     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.4062     Document Type: Article

References (50)

1. Beltrao, P., Cagney, G. & Krogan, N. J. Quantitative genetic interactions reveal biological modularity. Cell 141, 739-745 (2010).
2. Fischer, B. et al. A map of directional genetic interactions in a metazoan cell. eLife 4 (2015).
3. Drees, B. L. et al. Derivation of genetic interaction networks from quantitative phenotype data. Genome Biol. 6, R38 (2005).
4. St. Onge, R. P. et al. Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions. Nat. Genet. 39, 199-206 (2007).
5. Avery, L. & Wasserman, S. Ordering gene function: The interpretation of epistasis in regulatory hierarchies. TIG 8, 312-316 (1992).
6. Costanzo, M. et al. A global genetic interaction network maps a wiring diagram of cellular function. Science 353, aaf1420 (2016).
7. Wright, A. V., Nuñez, J. K. & Doudna, J. A. Biology and applications of CRISPR systems: harnessing nature's toolbox for genome engineering. Cell 164, 29-44 (2016).
8. Shalem, O., Sanjana, N. E. & Zhang, F. High-throughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 16, 299-311 (2015).
9. Boettcher, M. & McManus, M. T. Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol. Cell 58, 575-585 (2015).
10. O'Hare, T., Deininger, M. W., Eide, C. A., Clackson, T. & Druker, B. J. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin. Cancer Res. 17, 212-221 (2011).
11. Tanenbaum, M. E., Gilbert, L. A., Qi, L. S., Weissman, J. S. & Vale, R. D. A proteintagging system for signal amplification in gene expression and fluorescence imaging. Cell 159, 635-646 (2014).
12. Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
13. Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290 (2007).
14. Milojkovic, D. & Apperley, J. Mechanisms of resistance to imatinib and secondgeneration tyrosine inhibitors in chronic myeloid leukemia. Clin. Cancer Res. 15, 7519-7527 (2009).
15. de Jong, R., ten Hoeve, J., Heisterkamp, N. & Groffen, J. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J. Biol. Chem. 270, 21468-21471 (1995).
16. Cilloni, D. & Saglio, G. Molecular pathways: BCR-ABL. Clin. Cancer Res. 18, 930-937 (2012).
17. Cong, F. et al. Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation. Mol. Cell 6, 1413-1423 (2000).
18. Calvisi, D. F. et al. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J. Hepatol. 54, 311-319 (2011).
19. Kuo, T. C., Chavarria-Smith, J. E., Huang, D. & Schlissel, M. S. Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment. Mol. Cell. Biol. 31, 2566-2576 (2011).
20. Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6, 353-367 (2016).
21. Cheah, C. Y. et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 123, 3574-3577 (2014).
22. Li, F. et al. FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors. Cancer Discov. 5, 438-451 (2015).
23. Chase, A. et al. Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. Leukemia 23, 358-364 (2009).
24. Dufies, M. et al. Mechanisms of AXL overexpression and function in Imatinibresistant chronic myeloid leukemia cells. Oncotarget 2, 874-885 (2011).
25. Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186-191 (2015).
26. Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583-588 (2015).
27. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183 (2013).
28. Vojta, A. et al. Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res. 44, 5615-5628 (2016).
29. Dahlman, J. E. et al. Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. Nat. Biotechnol. 33, 1159-1161 (2015).
30. Stowe, I. B. et al. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 26, 1421-1426 (2012).
31. Graham, D. K., DeRyckere, D., Davies, K. D. & Earp, H. S. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat. Rev. Cancer 14, 769-785 (2014).
32. Gay, C. M., Balaji, K. & Byers, L. A. Giving AXL the axe: Targeting AXL in human malignancy. Br. J. Cancer 116, 415-423 (2017).
33. Postel-Vinay, S. & Ashworth, A. AXL and acquired resistance to EGFR inhibitors. Nat. Genet. 44, 835-836 (2012).
34. Sheridan, C. First Axl inhibitor enters clinical trials. Nat. Biotechnol. 31, 775-776 (2013).
35. Li, Z. et al. The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. Nat. Commun. 8, 14356 (2017).
36. Laufer, C., Fischer, B., Billmann, M., Huber, W. & Boutros, M. Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. Nat. Methods 10, 427-431 (2013).
37. Roguev, A. et al. Quantitative genetic-interaction mapping in mammalian cells. Nat. Methods 10, 432-437 (2013).
38. Bassik, M. C et al. A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 152, 909-922 (2013).
39. Vizeacoumar, F. J. et al. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol. Syst. Biol. 9, 696 (2013).
40. Shen, J. P. et al. Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions. Nat. Methods 14, 573-576 (2017).
41. Han, K. et al. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat. Biotechnol. 35, 463-474 (2017).
42. Blomen, V. A. et al. Gene essentiality and synthetic lethality in haploid human cells. Science 350, 1092-1096 (2015).
43. Du, D. et al. Genetic interaction mapping in mammalian cells using CRISPR interference. Nat. Methods 14, 577-580 (2017).
44. Kampmann, M., Bassik, M. C. & Weissman, J. S. Integrated platform for genome-wide screening and construction of high-density genetic interaction maps in mammalian cells. Proc. Natl. Acad. Sci. USA 110, E2317-E2326 (2013).
45. Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647-661 (2014).
46. LaMontagne, K. R. Jr., Flint, A. J., Franza, B. R. Jr., Pandergast, A. M. & Tonks, N. K. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Mol. Cell. Biol. 18, 2965-2975 (1998).
47. Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473-1475 (2014).
48. Burk, O. & Klempnauer, K. H. Myb and Ets transcription factors cooperate at the myb-inducible promoter of the tom-1 gene. Biochim. Biophys. Acta 1446, 243-252 (1999).
49. Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
50. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 343, 84-87 (2014).